Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT06245876
Official study title

Lung EpiCheck Biomarkers Development Study

Study summary

This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBlood collection

The study team can explain what participation involves.

Who it may be forEarly-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 30, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?10 U.S. locations

Locations may change over time.

Who runs it?Nucleix Ltd.

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Nucleix Ltd.
Interventions being studied
Other: Blood collection
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Early-stage or resectable→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Cases:
  • Age 50-80 years
  • Subjects who are currently smoking or former smokers, with at least 20 pack-years
  • Subjects with either A high suspicion for lung cancer, with planned biopsy or surgery to establish a definitive diagnosis within 60 days after enrollment or treatment naive lung cancer patients confirmed by pathology.
Reasons someone may not be able to joinExclusion criteria
  • Cases
  • Known diagnosis or treatment of cancer from any kind in the past 5 years, except of fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix and except from the current lung cancer Inclusion Criteria - USPSTF risk
  • Age 50-80 years
  • Subjects who are currently smoking or former smokers, with at least 20 pack-years

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Life Spring Clinical ResearchMiami, Florida
  • Emerald Coast OBGYNPanama City, Florida
  • Ochsner LSU Health Shreveport - Regional UrologyShreveport, Louisiana
  • Comprehensive UrologySouthfield, Michigan
  • Michigan Institute of Urology, P.C.Troy, Michigan
  • Urology San AntonioSan Antonio, Texas
  • National Koranyi Institute for PulmonologyBudapest
  • Carmel Medical CenterHaifa
  • Sourasky Medical CenterTel Aviv
  • ZGT Medical CenterHengelo

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 30, 2026. Always confirm current availability with the study team.

View original record ↗